Answers are grounded in this paper and cite their sources.
Background: Haemophilia is an inherited bleeding disorder due to failure of throm-bin generation resulting from clotting factor deficiency. In haemophilia A, the de-ficient factor is Factor VIII due to mutations in the F8 gene. In the past several decades, we have seen an unprecedented evolution of therapies for managing hae-mophilia A (Mahlangu, 2022) . These have included blood and blood products to plasma-derived concentrate, recombinant concentrate, concentrate with improvedpharmacokinetics and, more recently, non-replacement therapies. Notwithstandingthese advances in treatments, patients with haemophilia A (PwHA) remain withseveral unmet needs.
No takes yet. Share an insight, caveat, or question.
Johnny Mahlangu (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: